ARIAD Bolsters Its Global Management Team with 3 Recent Appointments

ARIAD Pharmaceuticals said that it recently appointed three executives with pharmaceutical industry experience in the areas of global quality, medical affairs, and drug safety and pharmacovigilance.

-Timothy Maines, Vice President, Quality

-Yan Moore, M.D., Vice President, Medical Affairs

-Piet A.M Vervaet, M.D., Vice President, Drug Safety and Pharmacovigilance

"As we continue to strengthen our oncology business in the United States and Europe, the recruitment of these three executives to our management team demonstrates our commitment to building a highly successful commercial oncology business," saidHarvey J. Berger, M.D., chairman and chief executive officer of ARIAD. "They exemplify our core values and bring many years of highly relevant experience to ARIAD in areas of fundamental importance to the Company. I am pleased to welcome Tim, Yan and Piet to ARIAD and look forward to their important contributions to our business."

In its release, the Company said that Maines leads the global quality function and has put in place systems to ensure quality and compliance in clinical, manufacturing and laboratory good practices. Maines brings over 20 years of leadership experience in quality operations and strategy to ARIAD.

Moore, M.D. leads global medical affairs and is responsible for investigator-sponsored clinical-research activities, publications, medical information, key therapeutic leader engagement, medical affairs planning for ARIAD's pipeline of oncology products and in collaboration with others, for life-cycle management of Iclusig (ponatinib) and strategic planning for its current and future clinical indications.

Vervaet, M.D. leads global safety and pharmacovigilance and is responsible for safety surveillance, risk identification and risk management for ARIAD's marketed and pipeline of oncology products, as well as proper risk communications to patients, healthcare professionals and health authorities. He also oversees, in collaboration with others, regulatory compliance with safety legislation for the Company's products.

More Information and Complete Details:

http://www.ariad.com

((Comments on this story may be sent to health@closeupmedia.com))